253 related articles for article (PubMed ID: 15094213)
21. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor.
Zhao XB; Lee RJ
Adv Drug Deliv Rev; 2004 Apr; 56(8):1193-204. PubMed ID: 15094215
[TBL] [Abstract][Full Text] [Related]
22. Folate-targeted hapten immunotherapy of adjuvant-induced arthritis: comparison of hapten potencies.
Yi YS; Ayala-López W; Kularatne SA; Low PS
Mol Pharm; 2009; 6(4):1228-36. PubMed ID: 19374407
[TBL] [Abstract][Full Text] [Related]
23. Depletion of folate-receptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus.
Varghese B; Haase N; Low PS
Mol Pharm; 2007; 4(5):679-85. PubMed ID: 17848087
[TBL] [Abstract][Full Text] [Related]
24. Hapten-directed targeting to single-chain antibody receptors.
Cheng TL; Liao KW; Tzou SC; Cheng CM; Chen BM; Roffler SR
Cancer Gene Ther; 2004 May; 11(5):380-8. PubMed ID: 15044963
[TBL] [Abstract][Full Text] [Related]
25. A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors.
Gawlick U; Kranz DM; Schepkin VD; Roy EJ
Bioconjug Chem; 2004; 15(5):1137-45. PubMed ID: 15366970
[TBL] [Abstract][Full Text] [Related]
26. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
Ross TL; Honer M; Lam PY; Mindt TL; Groehn V; Schibli R; Schubiger PA; Ametamey SM
Bioconjug Chem; 2008 Dec; 19(12):2462-70. PubMed ID: 19053298
[TBL] [Abstract][Full Text] [Related]
27. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors.
Lu Y; Low PS
Cancer Immunol Immunother; 2002 May; 51(3):153-62. PubMed ID: 11941454
[TBL] [Abstract][Full Text] [Related]
28. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
29. Exploitation of the folate receptor in the management of cancer and inflammatory disease.
Leamon CP; Jackman AL
Vitam Horm; 2008; 79():203-33. PubMed ID: 18804696
[TBL] [Abstract][Full Text] [Related]
30. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
[TBL] [Abstract][Full Text] [Related]
31. Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression.
Gottschalk S; Cristiano RJ; Smith LC; Woo SL
Gene Ther; 1994 May; 1(3):185-91. PubMed ID: 7584080
[TBL] [Abstract][Full Text] [Related]
32. Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies.
Henriksen G; Bruland OS; Larsen RH
Anticancer Res; 2005; 25(1A):9-15. PubMed ID: 15816513
[TBL] [Abstract][Full Text] [Related]
33. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates.
Leamon CP; Reddy JA; Dorton R; Bloomfield A; Emsweller K; Parker N; Westrick E
J Pharmacol Exp Ther; 2008 Dec; 327(3):918-25. PubMed ID: 18791065
[TBL] [Abstract][Full Text] [Related]
34. Folate-mediated targeting of therapeutic and imaging agents to cancers.
Reddy JA; Low PS
Crit Rev Ther Drug Carrier Syst; 1998; 15(6):587-627. PubMed ID: 9883391
[TBL] [Abstract][Full Text] [Related]
35. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
Chiu SJ; Marcucci G; Lee RJ
Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
[TBL] [Abstract][Full Text] [Related]
36. Antifolates targeted specifically to the folate receptor.
Jackman AL; Theti DS; Gibbs DD
Adv Drug Deliv Rev; 2004 Apr; 56(8):1111-25. PubMed ID: 15094210
[TBL] [Abstract][Full Text] [Related]
37. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues.
Thomas M; Kularatne SA; Qi L; Kleindl P; Leamon CP; Hansen MJ; Low PS
Ann N Y Acad Sci; 2009 Sep; 1175():32-9. PubMed ID: 19796075
[TBL] [Abstract][Full Text] [Related]
38. Roadmap to a better therapeutic tumor vaccine.
Emens LA
Int Rev Immunol; 2006; 25(5-6):415-43. PubMed ID: 17169782
[TBL] [Abstract][Full Text] [Related]
39. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
[TBL] [Abstract][Full Text] [Related]
40. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
